Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.38 +3.57%

+$0.06 today

Market cap
$193.57M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.43M

Average 1.03M

IKT EBITDA Margin

EBITDA as a percentage of revenue.

Inhibikase Therapeutics, Inc.NASDAQ: IKT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-7236.7%
Year-over-year change
+7383.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IKT compares with its peers on the latest reported figures

IKT Competitors Peer median
EBITDA Margin for IKT and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 2026102.6% +184.0 pp+219.6 pp
SRZNSurrozen, Inc.LTM Mar 2026-4567.0% -3876.5 pp-6672.9 pp
ENTXEntera Bio Ltd.FY2025-27164.3% -21926.2 pp-17559.8 pp
IKTInhibikase Therapeutics, Inc.FY2025— ——
TTRXTurn Therapeutics Inc.FY2025— ——
GLSIGreenwich LifeSciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
EXOZeXoZymes, Inc.FY2025— ——
Peer median (excluding IKT) -4567.0%-3876.5 pp-6672.9 pp

Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.1M123.44K260.5K00
Cost of Revenue11.36M6.72K13.62M26.27K0
Gross Profit(8.26M)116.72K(13.36M)(26.27K)0
Gross Margin-266.4%94.6%-5127.8%——
Research & Development11.36M12.03M13.62M17.21M29.79M
Selling, General & Admin06.21M6.73M11.38M23.56M
Operating Expenses6.51M18.25M6.73M28.56M51.97M
Depreciation & Amortization14.77M6.72K177.4K26.27K60.5K
EBITDA0(18.05M)(18.85M)(27.49M)(53.29M)
EBITDA Margin0.0%-14620.4%-7236.7%——
Operating Income(14.77M)(18.13M)(20.09M)(28.59M)(51.97M)
Operating Margin-476.2%-14686.2%-7712.0%——
Interest Income19.92K74.45K1.06M1.07M3.72M
Interest Expense19.92K74.45K000
Other Income / Expenses(19.92K)74.45K1.06M1.07M3.72M
Income Before Tax(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Pre-Tax Margin-476.9%-14625.9%-7304.8%——
Income Tax Expense00000
Net Income(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Net Margin-476.9%-14625.9%-7304.8%——
EPS (Basic)(4.88)(4.26)(3.57)(1.16)(0.49)
EPS (Diluted)(4.88)(4.26)(3.57)(1.16)(0.49)
Weighted Avg Shares3.03M4.2M5.33M69.36M98.31M
Weighted Avg Shares (Diluted)3.03M4.2M5.33M69.36M98.31M

Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.